The tweet was deleted by the author.
But we saved everything 🙂.
Artiva Biotherapeutics, Inc. will unveil five accepted abstracts featuring its AlloNK therapeutic at EULAR 2026. These presentations will cover clinical and translational findings across rheumatologic diseases, specifically focusing on refractory rheumatoid arthritis, Sjögren disease, and systemic sclerosis.
Among the highlights is a late-breaking oral presentation, underscoring the company’s ongoing research efforts in advancing next-generation immunotherapies for challenging autoimmune conditions.
Artiva recently reported initial positive results for its AlloNK therapy and announced plans to advance to a Phase 3 rheumatoid arthritis trial in 2026. The company continues to expand its clinical pipeline in rheumatologic diseases. AlloNK remains a central focus of its immunotherapy development program.